The DOI matches its Crossref record.
Complement activation predicts adverse pregnancy outcome in patients with systemic lupus erythematosus and/or antiphospholipid antibodies
Open accessAbstract
Objective Studies in mouse models implicate complement activation as a causative factor in adverse pregnancy outcomes (APOs). We investigated whether activation of complement early in pregnancy predicts APOs in women with systemic lupus erythematosus (SLE) and/or antiphospholipid (aPL) antibodies. Methods The PROMISSE Study enrolled pregnant women with SLE and/or aPL antibodies (n=487) and pregnant healthy controls (n=204) at <12 weeks gestation and evaluated them monthly. APOs were: fetal/neonatal death, preterm delivery <36 weeks because of placental insufficiency or preeclampsia and/or growth restriction <5th percentile. Complement activation products were measured on serial blood samples obtained at each monthly visit. Results APO occurred in 20.5% of SLE and/or aPL pregnancies. As early as 12–15 weeks, levels of Bb and sC5b-9 were significantly higher in patients with APOs and remained elevated through 31 weeks compared with those with normal outcomes. Moreover, Bb and sC5b-9 were significantly higher in patients with SLE and/or aPL without APOs compared with healthy controls. In logistic regression analyses, Bb and sC5b-9 at 12–15 weeks remained significantly associated with APO (ORadj=1.41 per SD increase; 95% CI 1.06 to 1.89; P=0.019 and ORadj=1.37 per SD increase; 95% CI 1.05 to 1.80; P=0.022, respectively) after controlling for demographic and clinical risk factors for APOs in PROMISSE. When analyses were restricted to patients with aPL (n=161), associations between Bb at 12–15 weeks and APOs became stronger (ORadj=2.01 per SD increase; 95% CI 1.16 to 3.49; P=0.013). Conclusion In pregnant patients with SLE and/or aPL, increased Bb and sC5b-9 detectable early in pregnancy are strongly predictive of APOs and support activation of complement, particularly the alternative pathway, as a contributor to APOs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Update οn the diagnosis and management of systemic lupus erythematosus
Fanouriakis, A., Tziolos, N., Bertsias, G., & Boumpas, D. T. (2021) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2020-218272 · Cited by 753
Interferons and Proinflammatory Cytokines in Pregnancy and Fetal Development
Yockey, L. J., & Iwasaki, A. (2018) · Immunity · doi:10.1016/j.immuni.2018.07.017 · Cited by 559
Antiphospholipid syndrome: advances in diagnosis, pathogenesis, and management
Knight, J. S., Branch, D. W., & Ortel, T. L. (2023) · BMJ · doi:10.1136/bmj-2021-069717 · Cited by 265
Self-citationImprovements in diagnosis and risk assessment of primary and secondary antiphospholipid syndrome
Petri, M. (2019) · Hematology · doi:10.1182/hematology.2019000046 · Cited by 11
Self-citation
Metadata
- Authors
- Kim, M. Y., Guerra, M. M., Kaplowitz, E., Laskin, C. A., Petri, M., Branch, D. W., Lockshin, M. D., Sammaritano, L. R., Merrill, J. T., Porter, T. F., Sawitzke, A., Lynch, A. M., Buyon, J. P., & Salmon, J. E.
- Venue
- Annals of the Rheumatic Diseases
- Publisher
- Elsevier BV
- Published
- 2018-04
- Volume
- 77
- Issue
- 4
- Pages
- 549-555
- ISSN
- 0003-4967 (ISSN-L)
- OpenAlex
- W2784510548
- Cited by
- 175
- References
- 0
- FWCI
- 13.58
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Complement activation predicts adverse pregnancy outcome in patients with systemic lupus erythematosus and/or antiphospholipid antibodies. https://app.cochat.ai/papers/10.1136/annrheumdis-2017-212224
- The paper
- Kim, M. Y., Guerra, M. M., Kaplowitz, E., Laskin, C. A., Petri, M., Branch, D. W., Lockshin, M. D., Sammaritano, L. R., Merrill, J. T., Porter, T. F., Sawitzke, A., Lynch, A. M., Buyon, J. P., & Salmon, J. E. (2018). Complement activation predicts adverse pregnancy outcome in patients with systemic lupus erythematosus and/or antiphospholipid antibodies. Annals of the Rheumatic Diseases. https://doi.org/10.1136/annrheumdis-2017-212224
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.